Articles tagged "Hepatitis C"

2021 American Transplant Congress
Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients
A. Demirag¹, P. L. Lobo², J. Oberholzer¹, A. Kumar², B. Rawashdeh¹, S. L. Lennon¹, H. N. Guvener Demirag¹, A. Doyle², J. Geystone³, K. L. Brayman¹
¹Transplantation, University of Virginia Medical Center, Charlottesville, VA, ²Transplantation Nephrology, University of Virginia Medical Center, Charlottesville, VA, ³Clinical Pharmacy, University of Virginia Medical Center, Charlottesville, VA
*Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…
2021 American Transplant Congress
Transplantation of Hepatitis C Positive Kidney and Pancreas Allografts Into Hepatitis C Naïve Recipients – A Single Center Experience as a Standard of Care
K. Yadav¹, A. Padiyar², K. Zhao³, J. Rabets³, A. Jittirat², S. Sclair⁴
¹Transplant Surgery, University of Toledo Medical Center, Toledo, OH, ²Nephrology, University Hospitals Cleveland, Cleveland, OH, ³Transplant Surgery, University Hospitals Cleveland, Cleveland, OH, ⁴Gastroenterology and Hepatology, University Hospitals Cleveland, Cleveland, OH
*Purpose: Transplantation of Hepatitis C positive organs into Hepatitis C naïve recipients is rapidly gaining widespread acceptance. We report our experience with transplanting HCV D+/R-…
2021 American Transplant Congress
One-year Outcomes of a Multicenter Trial of Transplantation of Hcv Viremic Kidney Donors into Hcv Uninfected Recipients
M. Sise¹, D. Goldberg², D. Schaubel³, J. Kort⁴, R. Alloway⁵, J. Friedewald⁶, R. Fontana⁷, S. Sultan⁸, N. Desai⁹, R. Chung¹, P. Reese¹⁰
¹Mass General Hospital, Boston, MA, ²U-Miami, Miami, FL, ³U. Pennsylvania, Philadelphia, PA, ⁴Abbvie, Chicago, IL, ⁵U Cincinnati, Cincinnati, OH, ⁶Northwestern U., Evanston, IL, ⁷U. Michigan, Ann Arbor, MI, ⁸Cornell, New York City, NY, ⁹Johns Hopkins, Baltimore, MD, ¹⁰U. Pennslyvania, Philadelpha, PA
*Purpose: As interest in transplantation of Hepatitis C virus (HCV)-viremic kidneys into HCV-uninfected (HCV+ to HCV- KT) recipients increases, understanding clinical outcomes beyond HCV clearance…
2021 American Transplant Congress
Exploring the Correlation with Donor Hepatitis C Viral Load and Viral Kinetics in Naïve Kidney Transplantation Recipients
A. Brooks¹, A. Rechnitzer¹, R. Teo¹, D. Y. Goldstein², M. Narlieva², J. P. Rocca¹, M. Ajaimy¹, L. Liriano-Ward¹, Y. Azzi¹, C. Pynadath¹, P. Loarte-Campos¹, E. Akalin¹, M. E. Le¹, H. Yaffe¹, S. Greenstein¹, J. Torabi¹, M. M. Kinkhabwala¹, J. A. Graham¹
¹Montefiore-Einstein Center for Transplantation, Montefiore Medical Center, Bronx, NY, ²Pathology, Montefiore Medical Center, Bronx, NY
*Purpose: The transplantation of Hepatitis C viremic (HCV) kidneys into uninfected recipients was made possible by effective direct acting anti-viral (DAA) therapy. This study aims…
2021 American Transplant Congress
Comprehensive Utilization of HCV Viremic and Non-Viremic Donor Livers and Kidneys into HCV-negative Patients
M. E. de Vera, J. Woloszyn, J. Sterris, M. Robinson, R. Evans, S. Blais, B. Elhazin, C. Amador, c. Berk, M. Volk, R. Villicana
Transplant Institute, Loma Linda University Health, San Bernardino, CA
*Purpose: We report our experience on virologic and graft outcomes of HCV-negative patients transplanted with HCV NAT+ (viremic) and HCV Ab+/NAT- (non-viremic) livers and kidneys…
2021 American Transplant Congress
Excellent Outcomes of Kidney Transplantation from Hepatitis C Infected Donors
B. Rawashdeh, J. Dann, K. M. Marsh, A. Doddi, S. Rao, A. Agarwal
UVA Health System, University of Virginia, Charlottesville, VA
*Purpose: Utilization of Hepatitis C viremic (HCV D+) kidney donors in HCV naïve recipients has increased in the United States. While there are shorter waiting…
2021 American Transplant Congress
Association of Donor Hepatitis C Virus Infection Status and Risk of Bk Polyomavirus Viremia After Kidney Transplantation
V. S. Potluri¹, D. E. Schaubel¹, M. E. Sise², B. P. Concepcion³, R. C. Forbes¹, E. A. Blumberg¹, D. Goldberg⁴, P. P. Reese¹, R. Bloom¹, D. Shaffer³, R. Chung², D. Sawinski¹, I. Strohben², N. Elias², A. Azhar⁵, M. Shah¹, J. Eason⁵, L. A. Binari³, M. Talwar⁵, V. Balaraman⁵, A. Bhalla⁵, B. Besharatian¹, M. Z. Molnar⁵
¹University of Pennsylvania, Philadelphia, PA, ²Massachusetts General Hospital, Boston, MA, ³Vanderbilt University Medical Center, Nashville, TN, ⁴University of Miami Miller School of Medicine, Miami, FL, ⁵Methodist University Hospital, Memphis, TN
*Purpose: Transplantation of kidneys from deceased donors with hepatitis C virus (HCV) infection into HCV-negative recipients has become more common, but some studies have suggested…
2021 American Transplant Congress
Alemtuzumab vs Antithymocyte Globulin Induction in Hepatitis C Viremic Donors to Hepatis C Negative Kidney Transplant Recipients
K. Walter, L. Mincemoyer, J. Giang, J. Suero, N. Shah, K. Szempruch
University of North Carolina Medical Center, Chapel Hill, NC
*Purpose: The optimal induction agent for kidney transplantation of hepatitis C virus nucleic acid test positive donors to negative recipients (HCV NAT D+/R-) is unknown.…
2021 American Transplant Congress
Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
G. Gupta, I. Yakubu, P. Kimball, L. Kang, K. Mitchell, M. Shinbashi, D. Kumar, I. Moinuddin, L. Kamal, A. King, C. Bhati, M. Levy, A. Cotterell, A. Sharma, R. Sterling
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…
2021 American Transplant Congress
Improving Liver Transplantation Outcomes for Hepatitis C Associated Hepatocellular Carcinoma in Direct-Acting Antiviral Therapy Era
K. Okumura, H. Sogawa, G. Veillette, D. John, T. Diflo, R. Bodin, D. C. Wolf, S. Nishida
Surgery, Westchester Medical Center/New York Medical College, Valhalla, NY
*Purpose: Direct-acting antiviral (DAA) therapy has transformed the outcomes of liver transplantation(LT) in patients with hepatitis C virus (HCV). The aim of this study was…